Get the Stockscreener App
0.945
0.78%
0.0073
After Hours:
.96
0.015
+1.59%
Lucid Diagnostics Inc stock is traded at $0.945, with a volume of 130.19K.
It is up +0.78% in the last 24 hours and up +16.65% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$0.9377
Open:
$0.95
24h Volume:
130.19K
Relative Volume:
0.59
Market Cap:
$46.63M
Revenue:
$2.43M
Net Income/Loss:
$-52.67M
P/E Ratio:
-0.6473
EPS:
-1.46
Net Cash Flow:
$-33.04M
1W Performance:
-4.01%
1M Performance:
+16.65%
6M Performance:
+1.65%
1Y Performance:
-26.74%
1-Day Range:
$0.9125
$0.95
1-Week Range:
$0.8894
$1.05
52-Week Range:
$0.6301
$1.58
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
Lucid Diagnostics expands direct contracting for cancer testing - Investing.com
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers - PR Newswire
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 - GuruFocus.com
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 - StockTitan
Lucid Diagnostics (NASDAQ:LUCD) Trading 1.5% HigherShould You Buy? - MarketBeat
Lucid Diagnostics (NASDAQ:LUCD) Trading 1.5% Higher – Here’s What Happened - Defense World
An unusual mascot and a former Cincinnati Bengal fight esophageal cancer - MM+M Online
Lucid Diagnostics to Participate in Upcoming Investor Conferences - GuruFocus.com
Lucid Diagnostics gets notice of allowance for patent underlying its esoguard esophageal DNA test - MSN
Lucid Diagnostics secures US patent for esophageal cancer test - Investing.com
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - StreetInsider.com
Lucid Diagnostics stock maintains Buy rating from BTIG - Investing.com India
Lucid Diagnostics stock maintains Buy rating from BTIG By Investing.com - Investing.com South Africa
Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players - Aktiellt
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care - StockTitan
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks - Benzinga
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit - PR Newswire
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024 - StreetInsider.com
Contrasting enVVeno Medical (NASDAQ:NVNO) and Lucid Diagnostics (NASDAQ:LUCD) - Defense World
Lucid Diagnostics Inc. (NASDAQ:LUCD) Position Trimmed by Nantahala Capital Management LLC - Defense World
Lucid Diagnostics' SWOT analysis: esophageal cancer screening stock faces pivotal year - Investing.com
Lucid Diagnostics Announces Multiple Presentations at the Upcomi - GuruFocus.com
Lucid Diagnostics Strengthens and Expands Market Access and Dire - GuruFocus.com
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
PAVMPAVmed Inc. Latest Stock News & Market Updates - StockTitan
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test - StockTitan
American Foregut Society's 2024 Annual Meeting to Highlight Luci - GuruFocus.com
Lucid Diagnostics to be deconsolidated from PAVmed’s financial statements - Medical Buyer
Lucid Diagnostics to be deconsolidated from PAVmed's financial statements - Seeking Alpha
PAVmed moves to deconsolidate Lucid Diagnostics - Investing.com
PAVmed moves to deconsolidate Lucid Diagnostics By Investing.com - Investing.com UK
PAVmed’s Strategic Overhaul to Secure Nasdaq Compliance - TipRanks
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements - StockTitan
Lucid Diagnostics (NASDAQ:LUCD) Given New $7.25 Price Target at Ascendiant Capital Markets - Defense World
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress - StockTitan
Lucid Diagnostics partners with Front Line to boost cancer detection in firefighters - Investing.com
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health - Yahoo Finance
Wall Street analysts’ outlook for Lucid Diagnostics Inc (LUCD) - SETE News
Stock Market Recap: Lucid Diagnostics Inc (LUCD) Concludes at 0.84, a -2.10 Surge/Decline - The Dwinnex
Lucid Diagnostics reports high accuracy in esophageal test study - Investing.com India
Behind Lucid Diagnostics Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
Analyzing LUCD’s current quarter earnings projections - US Post News
Lucid Diagnostics reports high accuracy in esophageal test study By Investing.com - Investing.com Australia
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer - Yahoo Finance
Lucid Diagnostics (NASDAQ:LUCD) Rating Reiterated by Canaccord Genuity Group - Defense World
Lucid Diagnostics Launches New Corporate Website - Longview News-Journal
PAVmed Inc (PAVM) Q2 2024 Earnings Call Transcript Highlights: R - GuruFocus.com
PAVmed’s EsoGuard revenue for Q2 2024 stands at USD 1.0M - Medical Buyer
Lucid Diagnostics (NASDAQ:LUCD) Lifted to Strong-Buy at Canaccord Genuity Group - Defense World
Cantor Fitzgerald stays bullish on Lucid Diagnostics, keeps $3 target - Investing.com
Lucid Diagnostics maintains Buy rating, $2.50 target amid growth By Investing.com - Investing.com Australia
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):